Alzheimer’s Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims
The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug results look more promising.
SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements
The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer's Clinical Trial
September 26, 2024) - The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Dr.
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
alzheimersnewstoday17h
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...
worldenergynews.com3h
Wall Street Journal Sept. 27
These are the most popular stories from the Wall Street Journal. These stories have not been verified and we cannot vouch their accuracy. U.S.
Cassava Sciences Unusual Options Activity For September 23
Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...
Biggest stock movers Friday: BB, BMY, and more
Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could of ...
Cassava Sciences, Inc.: Cassava Sciences Resolves SEC Investigation
Cassava Sciences, Inc. ("Cassava" or the "Company") (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has ...